Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population

  • Li, Hui-Yan (Department of Radiology, the Third Affiliated Hospital of Harbin Medical University) ;
  • Ge, Xin (Department of General Surgery, Heilongjiang Province's Hospital) ;
  • Huang, Guang-Ming (Department of General Surgery, Heilongjiang Province's Hospital) ;
  • Li, Kai-Yu (Department of General Surgery, Heilongjiang Province's Hospital) ;
  • Zhao, Jing-Quan (Department of General Surgery, Heilongjiang Province's Hospital) ;
  • Yu, Xi-Miao (Department of General Surgery, Heilongjiang Province's Hospital) ;
  • Bi, Wen-Si (Department of General Surgery, Heilongjiang Province's Hospital) ;
  • Wang, Yu-Lin (Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Medical College of Chinese People's Armed Police Force)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: Platinum agents have shown to be effective in the treatment of colorectal cancer. We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population. Methods: SNPs of GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln in 335 colorectal cancer patients were assessed using TaqMan nuclease assays. Results: At the time of final analysis on Nov. 2011, the median follow-up period was 37.7 months (range from 1 to 60 months). A total of 229 patients died during follow-up. Our study showed GSTP1 Val/Val (HR=0.44, 95% CI=0.18-0.98), ERCC1 C/C (HR=0.20, 95% CI=0.10-0.79) and ERCC2 G/G (HR=0.48, 95% CI=0.19-0.97) to be significantly associated with better survival of colorectal cancer. GSTP1 Val/Val, ERCC1 C/C and ERCC2 G/G were also related to longer survival among patients with colon cancer, with HRs (95% CIs) of 0.41 (0.16-0.91), 0.16 (0.09-0.74) and 0.34 (0.16-0.91), respectively. Conclusion: GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients.

Keywords

References

  1. Baek SK, Kim SY, Lee JJ, et al (2006). Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat, 38, 19-24. https://doi.org/10.4143/crt.2006.38.1.19
  2. Cao C, Zhang YM, Wang R, et al (2011). Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl), 124, 2203-8.
  3. Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37. https://doi.org/10.1016/S0006-2952(03)00260-0
  4. Han X, Xing Q, Li Y, et al (2012). Study on the DNA Repair Gene XRCC1 and XRCC3 Polymorphism in Prediction and Prognosis of Hepatocellular Carcinoma risk. Hepatogastroenterology, 59, doi: 10.5754/hge12096. [Epub ahead of print]
  5. International Agency for Research on Cancer (2008). Colorectal Cancer Incidence and Mortality Worldwide in 2008. 2011, http://globocan.iarc.fr.
  6. Ishibashi K, Okada N, Tajima Y, et al (2011). Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2 ( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase (MTHFD) in the primary lesion of colorectal cancer. Gan To Kagaku Ryoho, 38, 2220-3.
  7. Jun L, Haiping Z, Beibei Y (2009). Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly, 139, 724-8.
  8. Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148. https://doi.org/10.1186/1471-2407-8-148
  9. Kim KH, Kwon HC, Oh SY, et al (2011). Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers, 16, 74-82. https://doi.org/10.3109/1354750X.2010.533284
  10. Kweekel DM, Gelderblom H, Antonini NF, et al (2009). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer, 45, 572-8. https://doi.org/10.1016/j.ejca.2008.10.015
  11. Kweekel DM, Gelderblom H, Guchelaar HJ (2005). Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev, 31, 90-105. https://doi.org/10.1016/j.ctrv.2004.12.006
  12. Kwee S, Song MA, Cheng I, et al (2012). Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci, 5, 65-70. https://doi.org/10.1111/j.1752-8062.2011.00375.x
  13. Lascorz J, Bevier M, Schonfels WV, et al (2012). Polymorphisms in the mitochondrial oxidative phosphorylation chain genes as prognostic markers for colorectal cancer. BMC Med Genet, 13, 31.
  14. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol, 29, 4555-60.
  15. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. https://doi.org/10.1158/1078-0432.CCR-07-2238
  16. Noda E, Maeda K, Inoue T, et al (2012). Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology, 59, 130-3.
  17. Rajaraman P, Bhatti P, Doody MM, et al (2008). Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer, 123, 2713-6. https://doi.org/10.1002/ijc.23779
  18. Reed E (2005). ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2. https://doi.org/10.1158/1078-0432.CCR-05-1083
  19. Rouissi K, Bahria IB, Bougatef K, et al (2011). The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer, 11, 101. https://doi.org/10.1186/1471-2407-11-101
  20. Sato K (1989). Glutathione S-transferases as markers of preneoplasia and neoplasia. Adv Cancer Res, 52, 205-55. https://doi.org/10.1016/S0065-230X(08)60214-6
  21. Sharma RA, Dianov GL (2007). Targeting base excision repair to improve cancer therapies. Mol Aspects Med, 28, 345-74. https://doi.org/10.1016/j.mam.2007.06.002
  22. Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42. https://doi.org/10.1093/jnci/94.12.936
  23. Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU ⁄ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
  24. Storm HH, Engholm G, Hakulinen T, et al (2010). Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol, 49, 532-44. https://doi.org/10.3109/02841861003801148
  25. Sun JM, Ahn MJ, Park MJ, et al (2011). Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 80, 655-60. https://doi.org/10.1016/j.ijrobp.2010.02.061
  26. Townsend DM, Tew KD (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22, 7369-75. https://doi.org/10.1038/sj.onc.1206940
  27. Woolston CM, Zhang L, Storr SJ, et al (2012). The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Mod Pathol, Apr 6.
  28. Zha Y, Cun Y, Zhang Q, et al (2012). Prognostic Value of Expression of Kit67, p53, TopoIIa and GSTP1 for Curatively Resected Advanced Gastric Cancer Patients Receiving Adjuvant Paclitaxel plus Capecitabine Chemotherapy. Hepatogastroenterology, 59, 1327-32.
  29. Zhao Y, Deng X, Wang Z, et al (2012). Genetic Polymorphisms of DNA Repair Genes XRCC1 and XRCC3 and Risk of Colorectal Cancer in Chinese Population. Asian Pac J Cancer Prev, 13, 665-9. https://doi.org/10.7314/APJCP.2012.13.2.665

Cited by

  1. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis vol.35, pp.6, 2014, https://doi.org/10.1007/s13277-014-1746-y
  2. Elevated Mean Platelet Volume is Associated with Presence of Colon Cancer vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10501
  3. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients vol.17, pp.7, 2016, https://doi.org/10.2217/pgs-2015-0017
  4. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis vol.77, pp.6, 2016, https://doi.org/10.1007/s00280-016-3047-1
  5. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy vol.233, pp.3, 2018, https://doi.org/10.1002/jcp.25966
  6. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients vol.19, pp.1, 2018, https://doi.org/10.1186/s12881-018-0627-4